Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PPARG_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PPARG_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PPARG_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PPARG_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PPARG_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000609625 | Thyroid | HT | glycolytic process | 13/1272 | 81/18723 | 3.06e-03 | 2.46e-02 | 13 |
GO:005109110 | Thyroid | HT | positive regulation of DNA-binding transcription factor activity | 30/1272 | 260/18723 | 3.15e-03 | 2.52e-02 | 30 |
GO:0071372 | Thyroid | HT | cellular response to follicle-stimulating hormone stimulus | 4/1272 | 10/18723 | 3.19e-03 | 2.54e-02 | 4 |
GO:00435003 | Thyroid | HT | muscle adaptation | 17/1272 | 121/18723 | 3.35e-03 | 2.60e-02 | 17 |
GO:19040198 | Thyroid | HT | epithelial cell apoptotic process | 17/1272 | 121/18723 | 3.35e-03 | 2.60e-02 | 17 |
GO:00486598 | Thyroid | HT | smooth muscle cell proliferation | 23/1272 | 184/18723 | 3.40e-03 | 2.63e-02 | 23 |
GO:000675725 | Thyroid | HT | ATP generation from ADP | 13/1272 | 82/18723 | 3.41e-03 | 2.64e-02 | 13 |
GO:009025715 | Thyroid | HT | regulation of muscle system process | 29/1272 | 252/18723 | 3.79e-03 | 2.82e-02 | 29 |
GO:00486623 | Thyroid | HT | negative regulation of smooth muscle cell proliferation | 12/1272 | 75/18723 | 4.46e-03 | 3.20e-02 | 12 |
GO:0071371 | Thyroid | HT | cellular response to gonadotropin stimulus | 5/1272 | 17/18723 | 4.46e-03 | 3.20e-02 | 5 |
GO:00148235 | Thyroid | HT | response to activity | 12/1272 | 76/18723 | 4.98e-03 | 3.36e-02 | 12 |
GO:00434579 | Thyroid | HT | regulation of cellular respiration | 9/1272 | 49/18723 | 5.21e-03 | 3.48e-02 | 9 |
GO:00330027 | Thyroid | HT | muscle cell proliferation | 28/1272 | 248/18723 | 5.71e-03 | 3.72e-02 | 28 |
GO:19021703 | Thyroid | HT | cellular response to reactive nitrogen species | 5/1272 | 18/18723 | 5.83e-03 | 3.74e-02 | 5 |
GO:00435027 | Thyroid | HT | regulation of muscle adaptation | 14/1272 | 98/18723 | 6.35e-03 | 3.97e-02 | 14 |
GO:00508104 | Thyroid | HT | regulation of steroid biosynthetic process | 11/1272 | 69/18723 | 6.52e-03 | 4.06e-02 | 11 |
GO:000616525 | Thyroid | HT | nucleoside diphosphate phosphorylation | 14/1272 | 99/18723 | 6.94e-03 | 4.22e-02 | 14 |
GO:00148124 | Thyroid | HT | muscle cell migration | 15/1272 | 110/18723 | 7.44e-03 | 4.44e-02 | 15 |
GO:004603125 | Thyroid | HT | ADP metabolic process | 13/1272 | 90/18723 | 7.63e-03 | 4.50e-02 | 13 |
GO:004693925 | Thyroid | HT | nucleotide phosphorylation | 14/1272 | 101/18723 | 8.27e-03 | 4.78e-02 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPARG | SNV | Missense_Mutation | | c.724C>G | p.Leu242Val | p.L242V | P37231 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-A2-A0YC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | PD |
PPARG | SNV | Missense_Mutation | rs140204299 | c.1154N>A | p.Arg385Gln | p.R385Q | P37231 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPARG | SNV | Missense_Mutation | rs777334819 | c.235N>A | p.Glu79Lys | p.E79K | P37231 | protein_coding | tolerated_low_confidence(0.26) | benign(0.039) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
PPARG | SNV | Missense_Mutation | | c.724C>G | p.Leu242Val | p.L242V | P37231 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-OL-A66H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPARG | SNV | Missense_Mutation | novel | c.489N>G | p.Phe163Leu | p.F163L | P37231 | protein_coding | deleterious(0) | possibly_damaging(0.535) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
PPARG | insertion | Frame_Shift_Ins | novel | c.549_550insA | p.Ser186LysfsTer2 | p.S186Kfs*2 | P37231 | protein_coding | | | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PPARG | insertion | Nonsense_Mutation | novel | c.64_65insTGTTAGTAATGTAGGGATG | p.Ser22LeufsTer5 | p.S22Lfs*5 | P37231 | protein_coding | | | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPARG | SNV | Missense_Mutation | | c.181N>C | p.Asp61His | p.D61H | P37231 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.969) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
PPARG | SNV | Missense_Mutation | | c.1477N>T | p.Leu493Phe | p.L493F | P37231 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-G4-6307-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | SD |
PPARG | deletion | Frame_Shift_Del | | c.550delN | p.Ser186ValfsTer47 | p.S186Vfs*47 | P37231 | protein_coding | | | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | GTF505 | | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | BENSULIDE | BENSULIDE | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 135650496 | | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | SHINPTEROCARPIN | SHINPTEROCARPIN | 20022509 |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | TREPROSTINIL | TREPROSTINIL | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | modulator | CHEMBL490029 | MK-0533 | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | DICHLOROPHEN | DICHLOROPHEN | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | FLUDIOXONIL | FLUDIOXONIL | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | ETHYL EICOSAPENTAENOIC ACID | | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | AMORFRUTIN A | AMORFRUTIN A | 25938459 |